Document is current
Any future updates will be listed below
-
Authors
Thulin, Malin Hagberg
Ramberg, Håkon
Nielsen, Heidi Kristin
Grytli, Helene Hartvedt
Sivanesan, Shivanthe
Pandya, Abhilash D.
Seip, Kotryna
Andressen, Kjetil Wessel
Linder, Anna
Øijordsbakken, Miriam
Poutanen, Matti
Katz, Betina
Halvorsen, Bente
Mælandsmo, Gunhild Mari
Taskén, Kristin Austlid https://orcid.org/0000-0001-5530-4915
-
Funding
Funding for this research was provided by:
Kreftforeningen (181720, 5724658, 206202)
Cancerfonden (21 1889 Pj)
Stiftelsen Assar Gabrielssons Fond (FB23-105)
University of Oslo
- License Information
-
More Information
Article History
Received: 7 March 2025
Accepted: 21 May 2025
First Online: 17 June 2025
Declarations
:
: The animal experiments were performed according to the regulations of the Federation of European Laboratory Animals Science Association and were approved by the National Animal Research Authority (FOTS ID 4929) in Norway or by National Animal Research Authority (Ref. 171/214) in Sweden. The Prostate Cancer Biobank at OUS (REC 28144) provided serum samples from prostate cancer patients. Information about use of beta-blockers were obtained from the Norwegian Prescription Database (REC 17379).
: All the authors approved the final version of the manuscript and agreed to its publication.
: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
